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INTRODUCTION
For over 75 years radioiodine treatment has been the central post-surgical therapy for patients with differentiated thyroid cancer (DTC). However, at least a quarter of DTC patients do not uptake sufficient radioiodine ( 131 I) for effective ablation (1, 2), and this remains an urgent problem in metastatic disease. There are essentially two cohorts of thyroid cancer patients:
those who respond to radioiodine and have an excellent prognosis, and those who do not respond, and for whom outcome is dire (3). However, no substantial changes have been made to the way radioiodine is administered therapeutically, which might improve outcome.
Troublingly, DTC is now the most rapidly increasing cancer in the UK and US, with 300,000 new cases reported worldwide per annum, and more than 40,000 people whom die from thyroid cancer annually (4). Mechanisms which influence treatment success in radioiodine-resistant thyroid cancers have been described in elegant but fragmented investigations. Whilst undoubted clinical progress has been made (5-7) the underlying causes of treatment failure are still not fully understood, and the tumoural processes which underpin radioiodine success in individual patients need to be better delineated. (Table S2 ). In contrast, transient ARF4 overexpression resulted in significantly increased 125 I uptake in all three cellular settings ( Figure 1F and Figure S2B ), suggesting its impact on NIS function is bi-directional. A ~50-80% increase in 125 I uptake was further validated in VCP-siRNA-depleted TPC-1 and MDA-MB-231 NIS+ve cells, with human primary thyrocytes demonstrating a ~35% increase (Figure 1G and table S2). VCP induction by transient transfection reversed these effects, resulting in markedly repressed  125 I uptake in all three cell models ( Figure 1H and Figure S2C ).
Thus, we identify two novel modulators of NIS function which alter radioiodine uptake both in thyroid and breast cells lentivirally-transduced with NIS, and in human primary thyrocytes with endogenous NIS expression.
ARF4 and VCP bind NIS in vitro and modulate its expression
Having identified that manipulation of ARF4 and VCP expression altered radioiodine uptake, we sought to challenge our MS/MS data which indicated specific binding between each protein Together, these data suggest that whilst ARF4 potentiates NIS presence at the PM, VCP inhibits its expression at its key site of symporter activity.
ARF4 modulates NIS trafficking at the PM
Given that ARF4 and VCP overexpression were both associated with altered NIS PM expression, we next investigated their trafficking using HiLo microscopy. We identified that ARF4-dsRED and NIS-GFP trafficked in co-incident vesicles at the PM in HeLa cells ( Figure   3 , A and B and Figure S4 , A and B; Movie S1). By contrast, no such co-trafficking was apparent for VCP-dsRED and NIS-GFP, suggesting the site of functional interaction between VCP and NIS was distant to the PM ( Figure S4C and Movie S2). Of particular significance, in contrast to VCP, the presence of ARF4 led to an overall induction in both the mean velocity and distance travelled of NIS-GFP positive vesicles (P < 0.001; Figure 3 , C and D and Figure S5 , A to C).
In control experiments, we confirmed that NIS is endosomally trafficked in association with clathrin ( Figure S5D and Movie S3) and found a significant increase in the overall distance travelled by NIS-GFP in cells overexpressing clathrin ( Figure S5A ). We then appraised the impact of inhibiting clathrin-mediated endocytosis on NIS function using Dynasore. Treatment of NIS+ve cells overexpressing ARF4 with Dynasore resulted in significantly greater radioiodine uptake ( Figure 3E ) without any effect on total NIS protein levels ( Figure 3F and Figure S5E ), suggesting that ARF4 is not primarily enhancing NIS recycling to the PM.
ARF4 binds NIS via a C-terminal VXPX motif
ARF4 binds to the VXPX motif of Rhodopsin, which represents its four terminal amino acids (44). We identified two putative VXPX motifs within the extracellular loop of NIS at positions 475-478 (sequence VLPS) and in the NIS C-terminus at positions 574-577 (sequence VAPK).
Abrogation of both motifs (mutations 475ALAS478 and 574AAAK577) resulted in NIS proteins which retained endogenous functionality, but the 574AAAK577 NIS mutant could no longer be augmented in terms of radioiodine uptake by ARF4 overexpression in TPC-1 thyroid cells ( Figure 3G ). Co-IP assays demonstrated that 475ALAS478 mutant NIS still avidly bound ARF4, whereas 574AAAK577 mutant NIS lost interaction ( Figure 3H ). Hence, NIS has a VXPX ARF4 recognition sequence in its C-terminus which is required for ARF4 potentiation of function.
Overall, our results indicate that ARF4 and VCP appear to have different modes of action;
ARF4 is implicated in the trafficking of NIS to the PM, whereas VCP binds NIS and modulates NIS function elsewhere in the cell. In support of this, significantly altered total NIS protein levels were apparent in NIS+ve cells after siRNA ablation or exogenous expression of VCP but not following modulation of ARF4 expression ( Figure S6 , A and B).
Selective VCP inhibitors promote radioiodine uptake
VCP functions chiefly as a chaperone in disassembling protein complexes and facilitating the extraction and/or proteasomal degradation of proteins from the endoplasmic reticulum (ER), but is also implicated in a wider range of other cellular actions (45). Several specific VCP inhibitors already exist which target different facets of VCP structure or activity (46).
Critically, a significant induction of radioiodine uptake (>2.8-fold, Figure 4A ) was evident in
NIS+ve cells treated with the allosteric VCP inhibitor Eeyarestatin-1 (ES-1), which inhibits ER-cytosol dislocation and subsequent degradation of substrates (47, 48) . Similarly, the VCP inhibitor NMS-873, which is a potent and specific allosteric inhibitor of VCP capable of activating the unfolded protein response and inducing cancer cell death (49), yielded a significant 3-4-fold increase in radioiodine uptake in NIS+ve cells ( Figure 4B ).
Importantly, there were no significant reductions in cell viability at the optimal doses of VCP inhibitors used ( Figure S6C ), nor any changes in VCP protein expression ( Figure 4C ).
PLA and co-IP assays also revealed that NIS and VCP retained the ability to bind in the Figure S6D ). This important finding raises the possibility that VCP inhibitors can be used to induce radioiodine uptake in thyroid cells that have inherently repressed NIS function.
Dissecting the VCP mechanism of action
We next examined the dynamics of therapeutically targeting VCP function and found that ES-1 was associated with increased detectable NIS protein after 12 hours, accompanied by a concomitant increase in radioiodine uptake by 24 hours ( Figure 4H ). Similar data were apparent for NMS-873, although radioiodine uptake and NIS expression were detected at 6 In agreement with these findings, there was greater reduction of ARF4 expression in BRAFmutant PTC versus the non-BRAF mutant tumours ( Figure 6C ). The frequency of BRAF alterations was also higher in PTC (70.6%; n=139/197) with low ARF4 expression compared to PTC with high ARF4 (56.1%; n=110/196; Figure 6D ). By comparison, VCP expression was most significantly elevated in PTC with BRAF mutant, RET fusion and PAX8 fusion genes ( Figure 6E ). In contrast to ARF4, there was a similar frequency of BRAF alterations in PTC with either high or low VCP expression ( Figure 6F ).
Survival profiles in THCA are available for PTC patients treated with a range of radioiodine (RAI) doses, as well as those who have not received any radioiodine (i.e. non-RAI). We therefore evaluated whether VCP and ARF4 expression were associated with patient outcome and treatment. Overall, log-rank analysis using the entire cohort (n=413) did not detect any difference in survival between PTC patients with high tumoural VCP compared to those with low VCP (PL=NS), although a significant difference was evident at early (PB=0.016) and intermediate time-points (PT=0.022; Figure 6G ). Similarly to THCA, higher VCP expression was present in breast tumours versus normal tissue in the BRCA cohort ( Figure S8A ), which again failed to correlate with a significant reduction in survival (PL=NS; Figure S8B ).
A key finding however was that the subgroup of RAI-treated PTC patients with high tumoural VCP expression (n=195) had significantly reduced disease-free survival (DFS) than those with low VCP (PL=0.016; Figure 6H and Figure S8C ). By comparison, there was no significant difference in DFS of patients that did not receive RAI treatment when stratified on median tumoural VCP ( Figure 6I ). Cox regression analysis further highlighted that higher tumoural VCP in RAI-treated PTC patients was associated with an increased risk of recurrence (HR 3.57, 95% CI: 1.18 -10.86; Figure 6J ). Interestingly, the risk of recurrence was even to boosting the efficacy of radioiodine treatment, given that we are now close to having the necessary tools to restore NIS expression and iodide retention.
Here, we identified five structurally diverse allosteric inhibitors of VCP which all enhanced radioiodine uptake in vitro by a minimum of two-fold. Specific ARF4 agonists do not currently exist, and hence we pursued VCP inhibition as our central therapeutic strategy. CB-5083, the first-in-class inhibitor of VCP, was shown to be effective in inhibiting tumour growth in preclinical models (62) . Clinical trials of CB-5083 for solid and haematological malignancies however were recently prematurely terminated due to off-target effects on PDE6 resulting in ocular dysfunction (63) . To circumvent potential issues of toxicity we evaluated alternative drugs to enhance radioiodine uptake, of which two of them -ebastine and clotrimazole -are well tolerated in vivo and FDA-approved (55). Given that radioiodine uptake was enhanced within 24 hours of treatment, our findings necessitate the need for clinical trials to address whether patients receiving already well-tolerated doses of ebastine or clotrimazole at the time of radioiodine treatment uptake more 131 I than those given placebos. One important finding in support of this is that native, relatively de-differentiated thyroid cells which have negligible endogenous radioiodine uptake in our hands showed measurable NIS function following VCP inhibition.
Our MS/MS, co-IP and PLA assays all identified and confirmed ARF4 and VCP as new NIS interactors. The endocytosis of NIS is known to be modulated by the protein PBF (36).
Previously PBF which, unlike NIS, has a functional endocytosis motif (64), was the only protein shown to bind NIS and alter its subcellular localisation (36). We now identify the novel NIS interactor ARF4 binds NIS via a C-terminal 574VXPX577 motif to traffic NIS towards the PM and enhance NIS function.
We sought to apply new imaging technologies to address the cellular mechanisms of NIS trafficking. One surprising facet was the rapid trafficking of vesicles expressing both ARF4
and NIS, which hint at a more dynamic process of NIS trafficking than previously suggested.
ARF4 has a range of subcellular roles, from recruiting adaptor proteins for packaging proteins into vesicles destined for the PM, to recycling proteins from the PM through endosomes (65).
Our data suggest ARF4 is involved in the vesicular transport of NIS to the PM, given that inhibition of endocytosis had no impact on the ARF4-mediated increase in radioiodine uptake.
An important clinical observation was that high tumoural VCP expression, which acts predominately in the ER, and hence early in the progression of NIS to the PM, was strongly correlated with DFS, both overall, but particularly in patients who received radioiodine treatment. Similarly, PTC patients with low tumoural ARF4 expression who received higher doses of radioiodine (≥100 mCi) also had a significantly worse DFS. Our hypothesis is that high tumoural VCP expression in patients with PTC results in increased NIS degradation, hence permitting less NIS to be trafficked to the PM by ARF4, which we show is repressed in PTC. Thus, the function of NIS, which is already at very low expression levels or predominantly localized to intracellular compartments in PTC is further attenuated, resulting in worse DFS.
Several gaps in our knowledge remain. As a protein expressed mainly in basolateral membranes, cell polarisation is important to NIS function. There are no human polarised cell models which are physiologically relevant to thyroid cell biology, however. Despite this, our studies in non-polarised cell systems demonstrate a universal mechanism of NIS trafficking in transformed thyroid and breast cells, as well as primary thyrocytes. Further, since our dedifferentiated TPC-1 thyroid cells, as well as our MDA-MB-231 breast cells, are unlikely to express physiologically relevant levels of the TSH receptor, we did not investigate the potential effects of TSH -the canonical regulator of NIS -on NIS trafficking (66) . Our hypothesis is that TSH is more important to the expression of NIS than its direct trafficking. This reflects the surprising timescales of trafficking we observed in our HiLo microscopy; whereas TSH is known to influence NIS function over the course of hours and days (66) , vesicular movement of NIS close to the PM was unexpectedly dynamic. We thus propose that NIS function at the PM is a much more rapid process than currently envisaged.
Together, we now identify two proteins, VCP and ARF4, with critical roles in NIS function which correlate markedly with clinical outcome in PTC. In particular, VCP is specifically druggable with existing inhibitors resulting in clearly induced radioiodine uptake. Strategies
MATERIALS AND METHODS

Mass spectrometry
NIS-interactors were isolated by co-IP (anti-NIS antibody) and separated by SDS-PAGE.
Proteins were reduced, alkylated and trypsinised. Resulting peptides were separated on an acetonitrile gradient on the UltiMate 3000 HPLC (ThermoFisher Scientific). Eluted peptides passed through the AmaZon ETD ion trap and tandem mass spectrometer (Bruker). Mass spectra were processed using the Bruker DataAnalysis software and analyzed using the Mascot search engine (Matrix Science). Datasets were filtered based on peptide number, DAVID functional classification (67, 68) and literature review (69-73).
Western blotting, cell-surface biotinylation and co-IP assays
Western blotting and cell surface biotinylation assays (CSBA) were performed as described previously (36, 74, 75) . Blots were probed with specific antibodies (Table S3 ) and NIS expression quantified by densitometry in ImageJ relative to β-actin or Na + /K + ATPase, as indicated. Co-IPs were performed as described (36) except cell lysates underwent Dounce homogenisation to facilitate lysis.
HiLo microscopy and proximity ligation assay
Live cell HiLo microscopy was performed on an Olympus IX81 inverted fluorescence microscope. Images were acquired every 2 seconds for up to 5 minutes then integrated at 5 frames/second using the Olympus xCellence build 3554 software (see Movies S1 to 3). Mean velocity and distance travelled of NIS-GFP was quantified using the TrackMate plugin (ImageJ). The Duolink® in situ proximity ligation assay (PLA) was performed according to the manufacturer's instructions (Sigma-Aldrich).
Radioiodine uptake and inhibitors
Radioiodine (RAI; 125 I) uptake was performed as described previously (64) 
TCGA data analyses
Normalized gene expression data and clinical information were downloaded from TCGA via cBioPortal (76, 77) and FireBrowse (78) . In total, RNA-seq data for 501 THCA and 1093
BRCA TCGA samples were analyzed.
Statistical analyses
Data were analyzed using GraphPad Prism and Microsoft Excel. For comparison between two groups, data were subjected to the Student's t-test and Mann-Whitney U-test, and for multiple comparisons one-way ANOVA with Tukey's test for multiple comparisons and KruskalWallis tests were used. Primary thyrocyte data underwent log-transformation prior to analysis.
For DFS, the median value of VCP and ARF4 expression (log2) in TCGA was used to stratify patients with high or low expression. Subsequent analyses were completed using Kaplan-Meier curves and cohort comparisons were performed by the Log rank (PL) Breslow (PB) and TaroneWare (PT) tests. All grouped data are presented as mean ± SEM for three independent replicates unless otherwise stated, P < 0.05 was considered significant. (ii) Protein surveillance pathways exist that target NIS for ERAD. As VCP does not require ATPase activity to inhibit NIS function, it is likely that VCP acts to unfold NIS (iii) prior to proteasomal degradation, which, due to the constraint of pore size, would require NIS to be unstructured. (iv) ARF4 recognises the VAPK residues of the NIS C-terminus and promotes vesicular trafficking to the PM, where NIS is active (v). (vi) PBF has a YARF endocytosis motif and acts to bind and internalise NIS away from the PM in a clathrin-dependent process. (vii) Although inhibition of recycling by Dynasore suggests that ARF4 shuttles NIS to the PM, other proteins must promote recycling of NIS to the PM as with the majority of PM transporters.
